BACKGROUND: Stage II and III rectal cancers have been effectively treated with neoadjuvant chemoradiotherapy (NCRT) followed by definitive resection. Advancements in surgical technique and systemic therapy have prompted investigation of neoadjuvant multiagent chemotherapy (NMAC) regimens with the elimination of radiation (RT). The objective of the current study was to investigate factors that predict for the use of NCRT versus NMAC and compare outcomes using the National Cancer Data Base (NCDB) for select stage II and III rectal cancers. METHODS: In the NCDB, 21,707 patients from 2004 through 2012 with clinical T2N1 (cT2N1), cT3N0, or cT3N1 rectal cancers were identified who had received NCRT or NMAC followed by low anterior resection. Kaplan-Meier analyses, log-rank tests, and Cox-proportional hazards regression analyses were conducted along with propensity score matching analysis to reduce treatment selection bias. RESULTS: The 5-year actuarial overall survival (OS) rate was 75% for patients who received NCRT versus 67.2% for those who received NMAC (P <.01). On MVA, those who received NCRT had improved OS (hazard ratio, 0.77. P <.01), and this effect was confirmed on propensity score matching analysis (hazard ratio, 0.72; P 5.01). In the same model, the following variables improved OS: age < 65 years, having private insurance, treatment at an academic center, living in an affluent zip code, a low comorbidity score, receipt of adjuvant chemotherapy, and a shorter interval before surgery (all P <.05). African Americans, men, patients with highgrade tumors, those with cT3N1 tumors, and those who underwent incomplete (R1) resection had worse OS (all P <.05). CONCLU-SIONS: In this series, the elimination of neoadjuvant RT for select patients with stage II and III rectal adenocarcinoma was associated with worse OS and should not be recommended outside of a clinical trial. Cancer 2017;123:783-93.
INTRODUCTION
An estimated 40,000 new cases of rectal cancer are diagnosed in the United States annually. 1 Since 1990, the standard of care for stage II (T3 and T4 tumors) and stage III (N1 or N2 lymph node status) rectal cancer (with stage defined according to the American Joint Committee on Cancer staging system 2 ) has been trimodality therapy with radiation (RT), chemotherapy, and surgery. 3 Historical studies demonstrated that pelvic RT reduced local rectal cancer recurrence and increased the chance for sphincter preservation with surgery. [4] [5] [6] The sequencing of chemoradiotherapy (CRT) for stage II and III tumors was defined based on a landmark German randomized trial indicating that neoadjuvant CRT reduced local recurrence, improved sphincter preservation, and had an improved side-effect profile. 7, 8 These results were confirmed in the United States by the National Surgical and Adjuvant Breast and Bowel Project trial NSABP R-03. 9 Consequently, the standard of care for locally advanced rectal cancers is now preoperative CRT with 5-fluorouracil (5-FU) followed by surgical resection and additional adjuvant chemotherapy.
Recently, with the incorporation of total mesorectal excision (TME) surgical principles 10, 11 and improved systemic therapy, 12, 13 the benefit of pelvic radiation is being challenged. CRT is associated with short-term toxicity in 50% of patients as well as long-term effects, including fibrosis, fecal incontinence, bladder and sexual dysfunction, and myelosuppression. [14] [15] [16] [17] From a chemotherapy perspective, less toxicity has been reported with preoperative versus postoperative chemotherapy. 18 This rationale prompted the investigational use of neoadjuvant multiagent chemotherapy (NMAC) followed by excision, eliminating pelvic radiation, in a pilot trial that produced promising results. 19 The accruing PROSPECT trial is implementing this paradigm nationally for patients who have clinically staged T3N0 (cT3N0), cT3N1, and cT2N1 rectal cancer. 20 Given the small number of patients studied with this evolving regimen, we used the National Cancer Data Base (NCDB) to identify patients who appeared to meet eligibility criteria for the PROS-PECT trial to determine the impact of NMAC versus neoadjuvant chemoradiotherapy (NCRT) on overall survival (OS) and to determine variables that predicted for patients receiving NMAC versus NCRT.
MATERIALS AND METHODS

NCDB Criteria
The NCDB is a large, prospectively acquired database of patients from Commission on Cancer-accredited institutions across the United States that captures approximately 70% of all newly diagnosed malignancies in the United States. The data set includes detailed information on patient, disease, and treatment characteristics as well as survival outcomes. The NCDB includes detailed RT information regarding treatment site, radiation source, and dose as well as detailed surgical and pathologic information, including type of surgery, margin status, and number of lymph nodes removed.
The rectal NCDB was queried for patients aged >18 years who diagnosed during 2004 through 2012. Patients with cT2N1, cT3N0, and cT3N1 rectal adenocarcinomas who received NCRT or NMAC followed by a low anterior resection (LAR) were included. Patients who underwent abdominoperineal resection, did not receive neoadjuvant therapy, received nonmegavoltage photonbeam RT, or received single-agent chemotherapy alone and those who had medical reasons to not receive RT or had a lack of survival information were excluded (Fig. 1) 
Statistical Methods
Statistical analyses were conducted using SAS version 9.4 (SAS Inc, Cary NC) and SAS macros developed by the Biostatistics and Bioinformatics Shared Resource at Winship Cancer Institute. 23 Descriptive statistics for each variable were determined. Follow-up was assessed using the reverse Kaplan-Meier method. 24 The univariate association of each covariate with receipt of NCRT versus NMAC was assessed using the chi-square test for categorical covariates and an analyses of variance for numerical covariates. The primary endpoint of OS was measured in months from LAR to death from any cause or last followup if the patient remained alive. The univariate association (univariate analysis [UVA]) of each variable with OS was tested using Cox proportional hazards models and log-rank tests. A multivariable Cox proportional hazards model (multivariate analysis [MVA]) was fit by using a backward elimination method applying a P 5 .20 removal criterion. The effect of CRT versus NMAC on OS stratified by different variables was estimated by testing the interaction effect between each modality and each relevant variable. It is noteworthy that the variables lymphovascular space invasion, serum carcinoembryonic antigen, and tumor regression grade were eliminated from MVA because many patients were missing these data. KaplanMeier plots were produced to compare the survival curves by subgroups along with log-rank P values, and P < .05 was considered statistically significant.
Propensity score matching (PSM) was then used to address potential treatment selection bias. A logistic regression model predicting receipt of CRT versus NMAC was carried out to predict the propensity score by age, race, facility type and location, insurance status, county of residence, distance to treatment facility from home zip code, year of diagnosis, education and income level of home zip code, Charlson-Deyo score, lymph node status, T2N1 versus T3N0 versus T3N1 tumors, tumor grade, surgical margin, number of regional lymph nodes examined, time from the start of neoadjuvant therapy to surgery, and receipt of adjuvant chemotherapy. Patients who received NMAC were matched with those who received NCRT at a 1:5 ratio based on the propensity score using a greedy algorithm and an SAS macro provided by the Mayo Clinic. 25 The matching caliper was set at a 0.2 standard deviation of logit of the propensity score. After matching, the balance of covariates between 2 cohorts was evaluated using standardized differences, and a value of <0.1 was considered a negligible imbalance. 26 The effects were estimated in the matched sample using a Cox model with a robust variance estimator 27 for OS.
RESULTS
Patient Characteristics
In total, 21,707 patients met study entry criteria (Fig. 1) ; and, of these, 274 (1.3%) received NMAC. The median age at diagnosis was 60 years (range, 18-90 years). Overall, the median follow-up was 123.3 months. The median distance from a patient's zip code to the treatment facility was 11.2 miles. The median time from the end of neoadjuvant therapy to LAR was 62 days. For patients in the NCRT group, the median dose of RT was 50.4 grays (Gy) (range, 45-60 Gy). The median daily RT dose was 1.8 Gy. Table 1 summarizes the study population.
Predictors of Receipt of Neoadjuvant Treatment Type
On UVA, age < 65 years, Northeast and Midwest practice locations, having government insurance or a lack of insurance, patient's zip code within 50 miles of treatment facility, and treatment at community-based programs were demographic factors predictive of receiving NCRT. Lymph node-positive tumors (T2N1 or T3N1), attaining a complete pathologic response, and an interval from the end of neoadjuvant therapy to surgery of 1 to 3 months were tumor and treatment factors associated with the receipt of NCRT versus NMAC (all P < .05) (Supporting Table 1 ; see online supporting information). On MVA, patients who had a distance from home zip code to treatment facility <50 miles, a lack of insurance, and T3N1 tumors were more likely to receive NCRT versus NMAC (all P .01) (see Table 2 ).
Impact of Neoadjuvant Treatment Type on OS
The actuarial 5-year OS rate was 75% for patients who received NCRT compared with 67.2% for those who received NMAC (P < .01) (Fig. 2) . NCRT was associated with improved OS on UVA (hazard ratio [HR], 0.74; 95% confidence interval [CI], 0.58-0.93; P < .01) (Supporting Table 2 ; see online supporting information) and MVA (HR, 0.77; 95% CI, 0.61-0.97; P 5 .03). On MVA, additional variables associated with improved OS included age <65 years, treatment at an academic cancer program, having private insurance, living in a zip code with a median income >$46,000, Charlson-Deyo score of 0 or 1, having at least 12 lymph nodes examined during surgery, and LAR within 1 to 3 months from the end of neoadjuvant therapy (all P < .05) (see Table 3 ). Additional variables associated with worse OS on MVA included African American race, male gender, diagnosis between 2010 and 2012, poorly differentiated tumors, cT3N1 tumors, R1 resection, and not receiving adjuvant chemotherapy (all P < .05) (see Table 3 ). The receipt of NCRT did not have a significant interaction effect with tumor classification, facility type, or time from the end of neoadjuvant therapy to surgery on OS (all P > .10), indicating a benefit from NCRT across all levels of these variables.
Impact of Neoadjuvant Therapy on OS With PSM Analysis
After matching, PSM analysis identified 1343 patients who received NCRT and 274 who received NMAC, and the 2 groups were balanced on demographic, tumor, and treatment characteristics (Supporting Table 3 ; see online supporting information). On PSM analysis, the 5-year actuarial OS rate was 73.4 % for patients who received NCRT compared with 65.8% for those who received NMAC (P 5 .02) (Fig. 3) . In Cox analysis of the PSM patient cohorts, there was a statistically significant improvement in OS with NCRT (HR, 0.72; 95% CI, 0.56-0.93; P 5 .01).
DISCUSSION
In this analysis of the NCDB, we observed that, for patients with cT2N1, cT3N0, and cT3N1 rectal adenocarcinomas who underwent LAR, the receipt of NCRT versus NMAC was associated with improved OS on UVA, MVA, and interaction effect testing. This survival benefit persisted when PSM was implemented to balance the 2 cohorts for patient, tumor, and treatment characteristics. Our study is the first in the literature to compare these 2 neoadjuvant treatment strategies head-to-head and to examine factors that predict for treatment choice. We observed that patients who lived in a zip code within 50 miles of the treatment facility, who lacked insurance, and who had T3N1 tumors were more likely to receive NCRT. Our study also confirmed known poor prognostic factors in rectal cancer, including inadequate lymph node dissection, delay to surgery after neoadjuvant therapy, 28 incomplete resection, poorly differentiated tumors, and higher stage tumors. There is a movement to eliminate or reduce the use of NCRT in favor of NMAC in select patients, as evidenced by the ongoing PROSPECT trial, to decrease RTinduced toxicity. [14] [15] [16] [17] 29 The basis of this accruing trial is a pilot, single-arm, phase 2 study from Memorial SloanKettering Cancer Center that enrolled 32 patients. 19 Patients on that trial had clinically staged (on magnetic resonance imaging and endoscopic rectal ultrasound) T3 tumors (N0 or N1) that were deemed resectable and did not require temporary diverting ostomy or endorectal stent. Each patient received 4 cycles of modified 5-FU, leucovorin, and oxaliplatin (FOLFOX6) 30 with bevacizumab followed by 2 cycles of modified FOLFOX alone. If there was any progression, then patients instead received concurrent 5-FU and RT. From 3 to 6 weeks after they completed neoadjuvant chemotherapy, patients underwent surgery with TME. Adjuvant chemotherapy was personalized, and FOLFOX was recommended by the investigators. All patients underwent R0 resection, and 25% had a pathologic complete response. Only 2 patients required neoadjuvant RT because of FOLFOX intolerance, and 1 required adjuvant RT. The 4-year results were extremely promising, demonstrating 0% local recurrence and 91% OS 19 and prompting creation of the PROS-PECT trial. The PROSPECT trial randomizes patients with cT2N1, cT3N0, and cT3N1 rectal adenocarcinomas to receive 6 cycles of FOLFOX versus the standard, concurrent 5-FU and RT to 50.4 Gy. Patients in the FOL-FOX group are clinically and radiographically assessed on magnetic resonance imaging or endoscopic rectal ultrasound studies; and, if there is no progression and they have an estimated regression of 20%, then they proceed to LAR with TME. Patients who progress or have <20% regression receive standard, concurrent 5-FU and RT. Systemic chemotherapy is delivered after surgery, and adjuvant CRT is recommended for patients who do not achieve an R0 resection and did not undergo preoperative RT. The trial is currently enrolling patients at multiple sites in the United States. 20 There are several reasons for the interest in elimination of NCRT from the treatment paradigm in rectal cancer. Justification for the elimination of upfront RT in all patients with stage II and III rectal cancers comes from the low local recurrence rates observed with modern TME techniques, with overall 5-year estimates of less than 10%. 10, 11, 31 Moreover, randomized evidence indicates that RT improves local control in the TME era with no improvement in OS. 32 Improved systemic therapies, 12, 13, 33 with increasing pathologic complete responses and longer disease-free survival intervals, have also been used to rationalize the elimination of RT. However, beyond the above-mentioned single-arm study of 32 patients, there is a lack of prospective evidence for the elimination of RT in patients with stage II and III rectal cancers. A recently published Canadian review examining 566 patients who would meet eligibility for the PROS-PECT trial demonstrated that these patients had improved recurrence-free survival (HR, 0.75) compared with patients who did not meet enrollment criteria, suggesting that the elimination of RT could be considered. The current study has several strengths and limitations. The strengths include that our series serves as the largest assessment of the receipt of NMAC in patients with cT2N1, cT3N0, and cT3N1 disease and serves as the only comparison of these patients with those who received the current standard of care (NCRT). In addition, to our knowledge, we are the first to summarize these practice patterns in the United States and to report on factors that potentially influence clinicians' choice of treatment modality. The limitations of our study are the lack of uncaptured variables by the NCDB, like other cancer registries, leading to a potential inherent imbalance between the NCRT and NMAC groups. We performed stratified analysis, PSM analysis, and interaction variable testing to account for these confounding variables, and there was a persistent OS benefit from NCRT; however, even with these multiple statistical methods to balance the cohorts, there may be confounders that cannot be accounted for in the NCDB. We excluded patients who were coded as not being able to receive RT for medical reasons, but there may be confounding, uncaptured reasons why a patient did not receive RT that could impact OS. In addition, we could not determine specifically whether all patients in the NMAC would meet eligibility criteria for the PROSPECT trial. We can conclude that they are a similar cohort based on clinical stage, surgery modality, and their OS outcomes, but we do not have specific information on the methods used to stage these patients or on their clinical response before surgery. In addition, we could not capture specific chemotherapy regimens in the NCDB and could only determine whether patients had received multiagent chemotherapy in the NMAC group and single-agent chemotherapy in the NCRT group. Toxicity information and patient-reported outcomes are not reported, so we could not comment on the morbidity of the treatment regimens. Finally, the NCDB does not provide information on cause of death, and it is possible that the OS benefit from NCRT on stratified analysis was because of competing risks of death.
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CONCLUSION
In summary, our series indicates that the receipt of NCRT is associated with improved OS compared with NMAC on stratified analysis for select patients with stage II and III rectal adenocarcinomas who undergo LAR. This benefit persisted when demographic, tumor, and treatment variables were balanced. Patients who lived in a zip code within 50 miles of their treatment facility, had more advanced disease, and lacked insurance were more likely to receive NCRT instead of NMAC. Until results from the accruing PROSPECT trial are published, our series suggests that patients who have cT2N1, cT3N0, and cT3N1 rectal adenocarcinomas should receive NCRT, and NMAC should be reserved for clinical trials.
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